Nexomics Biosciences, a New Jersey-based start-up biotechnology company, agreed to license the rights to a portfolio of intellectual property provided by Rutgers, the State University of New Jersey.

The recently formed company will have access to a suite of bioinformatics software and an early stage antiobiotic screening process. Additionally, Nexomics may use and further develop a new ribosomal RNA methyltransferase assay, an invention that will affect control of bacteria and antibacterial therapy.

Nexomics applies emergent technologies for drug discovery projects based on significant protein production, nuclear magnetic resonance (NMR), and x-ray crystallography. It uses this process for identifying novel small molecule therapeutics.

The company also agreed with the Center for Advanced Biotechnology and Medicine, associated with Rutgers, for access to laboratory space and equipment to support molecular biology, fermentation, protein purification and NMR.

"Together with Professor Gaetano Monteleone and co-founder Dr. Michael Baran, Rutgers is very excited to create Nexomics as a tool for commercializing promising technologies out of Monteleone's lab," said Dr. Michael Pazzani, VP, Research and Graduate and Professional Education, Rutgers.